跳至主要内容
临床试验/JPRN-UMIN000015838
JPRN-UMIN000015838招募中未知

Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TAC - To evaluation of efficacy of switch to eribulin chemotherapy in breast cancer patients who are not responsive to TAC and continuation of TAC in responding patients to TAC

Saitama Medical Univeristy International Medical Center0 个研究点目标入组 40 人开始时间: 2014年12月3日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional,observational

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who do not have informed consent on paper Patients who have uncontroled severe diabetes, infection , or other malignancy Patients whom doctor consider this treatment are suitable for.

研究者

发起方
Saitama Medical Univeristy International Medical Center

相似试验